Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen cut shares of Arcturus Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·14d ago
More News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve ratings firms that are currently covering the...
MarketBeat·17d ago
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
Zacks·26d ago
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below 200 Day Moving Average - Should You Sell?
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve research firms that are currently covering the stock, MarketBeat...
MarketBeat·1mo ago
Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to "Hold"
Wall Street Zen upgraded shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·1mo ago
Arcturus Therapeutics (NASDAQ:ARCT) Price Target Lowered to $9.00 at Citigroup
Citigroup dropped their price target on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Thursday...
MarketBeat·1mo ago
Research Analysts Offer Predictions for ARCT FY2025 Earnings
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Research analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of Arcturus Therapeutics in a...
MarketBeat·1mo ago
William Blair Has Optimistic Outlook of ARCT FY2025 Earnings
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Stock analysts at William Blair lifted their FY2025 earnings estimates for shares of Arcturus Therapeutics in a research report...
MarketBeat·1mo ago
Arcturus Therapeutics (NASDAQ:ARCT) Given New $72.00 Price Target at Piper Sandler
Piper Sandler decreased their target price on shares of Arcturus Therapeutics from $140.00 to $72.00 and set an "overweight" rating on the stock in a report on Tuesday...